Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients

E. Lengliné, S. Chevret, A. S. Moreau, F. Pène, F. Blot, J. H. Bourhis, A. Buzyn, B. Schlemmer, G. Socié, E. Azoulay

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    71 Citations (Scopus)

    Résumé

    Intensive care unit (ICU) admission is associated with high mortality in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Whether mortality has decreased recently is unknown. The 497 adult allogeneic HSCT recipients admitted to three ICUs between 1997 and 2011 were evaluated retrospectively. Two hundred and nine patients admitted between 1997 and 2003 were compared with the 288 patients admitted from 2004 to 2011. Factors associated with 90-day mortality were identified. The recent cohort was characterized by older age, lower conditioning intensity, and greater use of peripheral blood or unrelated-donor graft. In the recent cohort, ICU was used more often for patients in hematological remission (67% vs 44%; P<0.0001) and without GVHD (73% vs 48%; P<0.0001) or invasive fungal infection (85% vs 73%; P=0.0003) despite a stable admission rate (21.7%). These changes were associated with significantly better 90-day survival (49% vs 31%). Independent predictors of hospital mortality were GVHD, mechanical ventilation (MV) and renal replacement therapy (RRT). Among patients who required MV or RRT, survival was 29% and 18%, respectively, but dropped to 18% and 6% in those with GVHD. The use of ICU admission has changed and translated into improved survival, but advanced life support in patients with GVHD usually provides no benefits.

    langue originaleAnglais
    Pages (de - à)840-845
    Nombre de pages6
    journalBone Marrow Transplantation
    Volume50
    Numéro de publication6
    Les DOIs
    étatPublié - 4 juin 2015

    Contient cette citation